Evaluation of Gastro Intestinal Stromal Tumor in a Tertiary Care Center
Main Article Content
Abstract
INTRODUCTION: Gastrointestinal stromal tumour (GIST) is an uncommon entity in clinical practice. It accounts for only <1% of all Gastrointestinal (GI) malignancies.
Stomach is the commonest site for this tumour. Other sites of GI tract are also affected with GIST.
AIMS AND OBJECTIVES: This study aimed evaluate the prognostic factors, and recurrence patterns among the patients of eastern India.
MATERIAL AND METHODS: This was a retrospective observational study which was conducted at the Department of Pathology in a tertiary care centre of eastern India. The specimens sent for HPE during the period June, 2018 to June, 2023 were included in the study. A total number of 2897 GI specimens sent to the Department for histopathological examinations were selected for the study. Out of which 77 specimens were diagnosed as GIST. The information of the vital parameters of the patient, type of tumour and type of treatments offered were collected for evaluation. The histological examinations relied on morphological features on Hematoxylin & Eosin stain and confirmation with immunohistochemistry markers CD34 and CD117 and S100. Patients with operable GIST underwent
Surgery followed by adjuvant therapy. Patients with inoperable/ borderline operable disease underwent neoadjuvant Tab. Imatinib 400 mg/day followed by reassessment for surgery.
RESULTS: The mean (±S.D.) age of the patients was 54.58±11.24 years with range of 28 -74 years and the median age was 54 years. 66.2% of the patients were with age< 60 years (p<0.001). Proportion of females (54.5%) was higher than males (45.5%) but it was not significant. Stomach (54.5%) was the most common site of tumour which was significantly higher than small intestine (27.3%) and large intestine (18.2%) (p<0.0001). At presentation non-metastatic cases (62.3%) were significantly higher than metastatic (35.1%) and locally recurrent cases (2.6%) (p<0.0001). In most of the cases the mitotic rate was between 5 – 10 /50 HPF (53.2%) which was significantly higher than mitotic rate <5/50 HPF (32.5%) and >10/50 (14.3%) (p=0.0042). Spindle cell type tumour (71.4%) was significantly higher than mixed (Spindle and Epithelioid) (20.8%) and Epithelioid type tumour (7.8%) (p<0.0001).
CONCLUSION: GIST is a rare tumor of the GI tract. It usually occurs in the stomach. The treatment of choice is surgery followed by adjuvant therapy.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. AmSurgPathol. 1983;7:507–519
II. Perez-Atayde AR, Shamberger RC, Kozakewich HW. Neuroectodermal differentiation of the gastrointestinal tumors in the Carney triad. An ultrastructural and immunohistochemical study. Am J Surg Pathol. 1993;17:706–714. [PubMed] [Google Scholar
III. Schaefer IM, Mariño-Enríquez A, Fletcher JA. What is New in Gastrointestinal Stromal Tumor? Adv Anat Pathol. 2017 Sep;24(5):259-267. doi: 10.1097/PAP.0000000000000158. PMID: 28632504; PMCID: PMC5608028.
IV. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for Schaefer IM, Mariño-Enríquez A, Fletcher JA. What is New in Gastrointestinal Stromal Tumor? Adv Anat Pathol. 2017 Sep;24(5):259-267. doi: 10.1097/ PAP.0000000000000158. PMID: 28632504; PMCID: 1
V. Cuccaro F, Burgio Lo Monaco MG, Rashid I, et al. Population-based incidence of gastrointestinal stromal tumors in Puglia. Tumori Journal. 2021;107(1):39-45. doi:10.1177/0300891620931944
VI. Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015; 24:298–302. doi: 10.1158/1055-9965.EPI-14-1002
VII. Sridharan, S., Kumar, R., Dinesh, K., Sundaravadanan, B., Kirouchenaradj, V. and Balamurali, S. (2020) Small Intestine Gastrointestinal Stromal Tumour—A Case Report. Case Reports in Clinical Medicine, 9 (1), 7-14. doi: 10.4236/ crcm.2020.91002.
VIII. Lakshmaiah KC, Suresh TM, Babu G, Babu S, Purohit S, Guruprasad B, and Jacob L, Loknath D (2014) gastrointestinal stromal tumors: a single institute experience from South India. Clin Cancer Investig J 3:62– 65.
IX. Dutta S, Ghosh BN, Pal RD, Pandey P, Mukhopadhyay M, Saklani A et al An audit of gastrointestinal stromal tumors from a tertiary medical college hospital in Eastern, India. Asian J Oncol ; 2018 ,4: 6–10
X. Ravikumar G, Kalegowda IY, Ananthamurthy A (2011) Clinicopathologic spectrum of gastro intestinal stromal tumours - experience at a tertiary care center. Indian J Cancer 48:466–470
XI. Lakshmi VA, Chacko RT, Kurian S. Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital. Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):628-33. doi: 10.4103/0377-4929.72005. PMID: 21045382.
XII. Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y,et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J ClinOncol 2007; 12:369-74.
XIII. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: de- pendence on anatomic site. Am J SurgPathol 23:82–87
XIV. DeMatteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608–615
XV. Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clini- copathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J SurgPathol 30:477–489
XVI. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13:265–274
XVII. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465
XVIII. Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Wozniak A, Limon J et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann SurgOncol 14:2018–2027
XIX. Cho MY, Sohn JH, Kim JM, Kim KM, Park YS, Kim WH, Jung JS, Jung ES, Jin SY, Kang DY, Park JB, Park HS, Choi YD, Sung SH, Kim YB, Kim H, Bae YK, Kang M, Chang HJ, Chae YS, Lee HE, Park DY, Lee YS, Kang YK, Kim HK, Chang HK, Hong SW, Choi YH, Shin O, Gu MJ, Kim YW, Kim GI, Chang SJ (2010) Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. J Korean Med Sci 25:853–862
XX. Barry RG, Wolbert TT, Denning DA. Gastrointestinal Stromal Tumors (GIST) [Internet]. Gastrointestinal Surgery - New Technical Proposals. InTech; 2018. Available from
XXI. Varshney VK, Gupta RK, Saluja SS, Tyagi I, Mishra PK, Batra VV. Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors. Indian J Cancer. 2019 Apr-Jun;56(2):135-143. doi: 10.4103/ijc.IJC_352_18. PMID: 31062732.
XXII. Keung EZ, Raut CP (2017) Management of gastrointestinal stromal tumors. SurgClin N Am, 2017 97:437–452
XXIII. Wang, M., Xu, J., Zhang, Y. et al. Gastrointestinal stromal tumor: 15-years’ experience in a single center, BMC Surg, 2014, 14, 93 : 1-10
XXIV. Madhumita Mukhopadhyay, Rituparna Kayal, Subhamoy Saha, Malobika Baisya, Binata Bandopadhyay3, Biswanath Mukhopadhyay ; An Uncommon Tumor in Stomach in A Young Girl, International Journal of Pharmaceutical and Bio-Medical Science, 2024 :04 (03)Issue 03 : 188-191